A number of firms have modified their ratings and price targets on shares of Illumina (NASDAQ: ILMN) recently:
- 11/17/2026 – Illumina was downgraded by Weiss Ratings from “buy (b-)” to “hold (c)”.
- 11/16/2026 – Illumina was given a new $235.00 price target by Jefferies Financial Group. They now have a “hold” rating on the stock.
- 11/7/2026 – Illumina was downgraded by Wall Street Zen from “buy” to “hold”.
- 11/2/2026 – Illumina was upgraded by Weiss Ratings from “hold (c)” to “buy (b-)”.
- 11/2/2026 – Illumina had its price target raised by Citigroup from $113.00 to $210.00. They now have a “sell” rating on the stock.
- 10/30/2026 – Illumina had its “underperform” rating reaffirmed by Evercore.
- 10/30/2026 – Illumina had its price target lowered by JPMorgan Chase & Co. from $320.00 to $300.00. They now have an “overweight” rating on the stock.
- 10/23/2026 – Illumina was downgraded by Stephens from “overweight” to “equal weight”. They now have a $275.00 price target on the stock.
- 10/23/2026 – Illumina was downgraded by Stephens from “overweight” to “equal weight”. They now have a $275.00 price target on the stock.
- 10/19/2026 – Illumina had its price target raised by Canaccord Genuity Group from $205.00 to $300.00. They now have a “hold” rating on the stock.
- 10/13/2026 – Illumina had its price target raised by TD Cowen from $210.00 to $270.00. They now have a “hold” rating on the stock.
- 10/11/2026 – Illumina was upgraded by Wall Street Zen from “hold” to “buy”.
- 10/7/2026 – Illumina had its price target raised by Barclays from $160.00 to $200.00. They now have an “underweight” rating on the stock.
- 10/5/2026 – Illumina had its price target raised by Royal Bank Of Canada from $230.00 to $310.00. They now have an “outperform” rating on the stock.
- 10/3/2026 – Illumina was downgraded by Wall Street Zen from “buy” to “hold”.
- 10/1/2026 – Illumina had its price target raised by Guggenheim from $226.00 to $305.00. They now have a “buy” rating on the stock.
- 9/29/2026 – Illumina had its price target raised by Leerink Partners from $220.00 to $300.00. They now have an “outperform” rating on the stock.
- 9/28/2026 – Illumina had its price target raised by Piper Sandler from $225.00 to $305.00. They now have an “overweight” rating on the stock.
Illumina Stock Down 4.3%
NASDAQ ILMN traded down $8.99 during midday trading on Thursday, hitting $201.02. 1,101,327 shares of the company traded hands, compared to its average volume of 2,168,702. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35. The company’s 50-day simple moving average is $248.55 and its 200-day simple moving average is $180.47. The company has a market cap of $30.39 billion, a PE ratio of 34.60, a price-to-earnings-growth ratio of 2.75 and a beta of 1.46. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05.
Illumina (NASDAQ:ILMN – Get Free Report) last announced its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.34 EPS. As a group, equities research analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current year.
Insider Activity
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
Further Reading
- Five stocks we like better than Illumina
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with MarketBeat.com's FREE daily email newsletter.
